Frontier Wealth Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Frontier Wealth Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-72,600	Closed	-$971K	–	443
2021 Q2	$971K	Hold	72,600	–	–	0.07%	185
2021 Q1	$738K	Buy	72,600 +700	+1%	+$5.75K	0.06%	202
2020 Q4	$305K	Hold	71,900	–	–	0.03%	291
2020 Q3	$188K	Hold	71,900	–	–	0.02%	342
2020 Q2	$254K	Hold	71,900	–	–	0.02%	297
2020 Q1	$219K	Buy	+71,900	New	+$315K	0.04%	257

Other funds holding ORMP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

Jetstream Capital Brentwood, Tennessee $1.37M AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Frontier Wealth Management's ORMP Position: Q3 2021 in Review

Frontier Wealth Management sold out of Oramed Pharmaceuticals (ORMP) in Q3 2021, closing a stake of 72,600 shares — an estimated $971K sold.

Frontier Wealth Management first reported a position in ORMP in Q1 2020 and held it in 6 quarters. The position peaked at $971K in Q2 2021. 93 funds tracked by Wall St. Rank hold ORMP as of Q3 2021.

Frontier Wealth Management reported no remaining Oramed Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Frontier Wealth Management sold 72,600 Oramed Pharmaceuticals shares in Q3 2021, an estimated $971K.
Frontier Wealth Management first reported a position in Oramed Pharmaceuticals in Q1 2020 and held it in 6 quarters.
Frontier Wealth Management's Oramed Pharmaceuticals position peaked at $971K in Q2 2021.
93 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2021.

Based on Frontier Wealth Management's 13F filing for Q3 2021, filed 12 Nov 2021.